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Tonic activation of A2A adenosine receptors unmasks, and of A1
receptors prevents, a facilitatory action of calcitonin gene-related
peptide in the rat hippocampus
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1 We investigated how manipulations of the degree of activation of adenosine A1 and A2A
receptors influences the action of the neuropeptide, calcitonin gene-related peptide (CGRP) on
synaptic transmission in hippocampal slices. Field excitatory post-synaptic potentials (EPSPs) from
the CA1 area were recorded.
2 When applied alone, CGRP (1 – 30 nM) was without eect on field EPSPs. However, CGRP
(10 – 30 nM) significantly increased the field EPSP slope when applied to hippocampal slices in the
presence of the A1 receptor antagonist, 1,3-dipropyl-8-cyclopenthyl xanthine (DPCPX, 10 nM), or in
the presence of the A2A adenosine receptor agonist CGS 21680 (10 nM).
3 The A2A receptor antagonist, ZM 241385 (10 nM) as well as adenosine deaminase (ADA,
2 U ml71), prevented the enhancement of field EPSP slope caused by CGRP (30 nM) in the presence
of DPCPX (10 nM), suggesting that this eect of CGRP requires the concomitant activation of A2A
adenosine receptors by endogenous adenosine.
4 The protein kinase-A inhibitors, N-(2-guanidinoethyl)-5-isoquinolinesulfonamide (HA-1004,
10 mM) and adenosine 3’,5’-cyclic monophosphorothioate, Rp-isomer (Rp-cAMPS, 50 mM), as well
as the inhibitor of ATP-sensitive potassium (KATP) channels, glibenclamide (30 mM), prevented the
facilitation of synaptic transmission caused by CGRP (30 nM) in the presence of DPCPX (10 nM),
suggesting that this eect of CGRP involves both KATP channels and protein kinase-A.
5 It is concluded that the ability of CGRP to facilitate synaptic transmission in the CA1 area of
the hippocampus is under tight control by adenosine, with tonic A1 receptor activation by
endogenous adenosine ‘braking’ the action of CGRP, and the A2A receptors triggering this action.
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Introduction
Adenosine, by operating inhibitory A1 receptors or excitatory
A2 receptors, has widespread modulatory actions in the
nervous system (for a review see Sebastia˜o & Ribeiro, 1996)
and may interfere with the action of other neuromodulator/
neurotransmitter substances (Ribeiro, 1999). Of particular
interest in the context of the present study are the evidences
that A2A receptor activation inhibits A1 receptor function in
the hippocampus (Cunha et al., 1994) and that tonic activation
of adenosine A2A receptors facilitates the action of other
neuromodulators, such as that of the neuropeptide calcitonin
gene-related peptide (CGRP) at motor nerve terminals
(Correia-de-Sa´ & Ribeiro, 1994). Adenosine, through A1
receptor activation, may also interfere with CGRP release
(Santicioli et al., 1993).
CGRP is a 37-amino acid peptide generated from the
calcitonin gene by alternate tissue-specific splicing (Amara et
al., 1982). It is widely present in the peripheral and in the
central nervous system (for reviews see Ishida-Yamamoto &
Tohyama, 1989; Poyner, 1992), including the hippocampus
(Bulloch et al., 1996; Freund et al., 1997; Oliver et al., 1999),
where it inhibits NMDA receptor-mediated actions (Bouchard
et al., 1995) and may protect against injury (Bulloch et al.,
1996; 1998).
The present work was designed to investigate how
manipulations of the degree of activation of adenosine A1 and
A2A receptors influences the action of CGRP on synaptic
transmission in the hippocampus. Since the predominant
action of endogenous adenosine on synaptic transmission in
the hippocampus is inhibitory, through A1 receptor activation
(e.g. Dunwiddie & Diao, 1994), we first evaluated how
blockade of A1 receptors could influence the action of CGRP.
Because synaptic transmission in the hippocampus can be
influenced by both inhibitory A1 (Sebastia˜o et al., 1990) and
excitatory A2A (Sebastia˜o & Ribeiro, 1992) adenosine
receptors, we then investigated how the simultaneous blockade
of these two adenosine receptor subtypes, and how removal of
endogenous extracellular adenosine with adenosine deaminase,
could influence the eect of CGRP. How A2A adenosine
receptor activation by a selective agonist interferes with the
action of CGRP on hippocampal synaptic transmission, was
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also evaluated. Since several CGRP-mediated action involve
activation of protein-kinase A and of ATP-sensitive potassium
channels (KATP channels) (e.g. Zang et al., 1994; Santicioli &
Maggi, 1994; Wellman et al., 1998), we investigated how
inhibition of PK-A with HA-1004 (Hidaka & Kobayahi, 1992)
or with the cyclic AMP analogue, RpcAMPS (Rothermel &
Parker-Bothelho, 1998) and how inhibition of KATP channels
with glibenclamide (Schmid-Antomarchi et al., 1987) aects
the action of CGRP on synaptic transmission in the
hippocampus.
A preliminary account of this study has been presented to
the 6th International Symposium of Adenosine and Adenine
Nucleotides, in Ferrara, Italy, May 1998 (Sebastia˜o et al.,
1998) and to the British Pharmacological Society (Sebastia˜o et
al., 1999)
Methods
The experiments were performed on hippocampal slice
preparations taken from male Wistar rats (5 – 6 weeks old)
handled according to the European Community guidelines on
Animal Care. The animals were decapitated under halothane
anaesthesia and the hippocampus dissected free into ice-cold
Krebs solution of the following composition (mM): NaCl 124,
KCl 3, NaH2PO4 1.25, NaHCO3 26, MgSO4 1, CaCl2 2,
glucose 10, previously gassed with 95% O2/5% CO2 (pH&7.4).
Slices (400 mm thick) were cut perpendicular to the long axis of
the hippocampus with a McIlwain tissue chopper, and allowed
to recover for at least 1 h in a chamber within the same gassed
medium at room temperature (22 – 258C). A slice was then
transferred to a 1 ml (plus 2 ml dead volume) recording
chamber for submerged slices and continuously superfused
with gassed bathing solution at 308C, at a flow rate of
3 ml min71. Drugs were added to this superfusion solution.
Monopolar stimulation (rectangular pulse of 0.1 ms applied
once every 10 s) was delivered through a concentric electrode
placed on the Schaer collateral/commissural fibres, in the
stratum radium near the CA3/CA1 border. Evoked field
excitatory post-synaptic potentials (field EPSPs) were recorded
through an extracellular electrode (4 M NaCl, 3 – 5 MO
resistance) placed in the stratum radiatum of the CA1 area.
The intensity of the stimulus (80 – 400 mA) was initially
adjusted to obtain a large field EPSP slope with a minimum
population spike contamination. Recordings were obtained
with an Axoclamp 2B amplifier coupled to a DigiData 1200
interface (Axon Instruments). Averages of eight consecutive
responses were continuously monitored on a personal
computer with the LTP program (Anderson & Collingridge,
1997), kindly supplied by W.W. Anderson (University of
Bristol, U.K.). Responses were quantified as the slope of the
initial phase of the averaged field EPSPs, since slope measures
are considered a more accurate measure of field EPSP
magnitude than the amplitude, due to contamination by
population spike.
To minimise underestimation of the CGRP responses due
to desensitization (see Aiyar et al., 1992), only one
concentration of CGRP was applied to each slice, and thus,
the concentration response curves showed in this paper were
performed in a non-cumulative manner. CGRP was applied to
each slice either alone or in the presence of adenosine receptor
agonists and/or antagonists. Whenever the eect of CGRP was
tested in the presence of other drugs, the neuropeptide was
applied to the preparations only after a stable response to these
drugs was observed and at least 20 min after starting their
perfusion. Because CGRP is readily adsorbed onto plastic and
glass, the chamber and all the connecting tubes were pre-
treated with Sigmacote to minimise losses of the peptide (see
Afonso et al., 1996).
Drugs
Rat calcitonin gene-related peptide (CGRP) and sigmacote
were from Sigma. CGS 21680 (2-[p-(2-carboxyethylphenethy-
lamino]-5’-N-ethylcarboxamide adenosine) and 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX) were from Research Biochem-
icals Inc. (R.B.I.). ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]-
triazolo[2,3-a][1,3,5]triazin-5ylamino]ethyl)phenol), was a kind
gift from ZENECA. DPCPX was made up in a 5 mM stock
solution in 99% dimethylsuphoxide (DMSO)/1% NaOH1 M
(v v71). CGS 21680 and ZM 241385 was made up in 5 mM
stock solutions in DMSO. CGRP was made up as a 1 mM
stock solution in distilled water. Aliquots of the stock solutions
were kept frozen at 7208C until use. In each experiment, one
aliquot was thawed and diluted in Krebs solution.
Analysis of the data
The data are expressed as means+s.e.mean from n number of
slices. Unless otherwise stated, the significance of the
dierences between the means was evaluated by the Student’s
t-test. When comparing more than two experimental groups
(Figure 3), one-way repeated measures ANOVA was used
followed by the Newman-Keuls test. Values of P50.05 were
considered to represent statistically significant dierences.
Results
Influence of A1 receptor blockade upon the eect of
calcitonin gene-related peptide (CGRP) on hippocampal
synaptic transmission
To prevent A1 receptor activation by endogenous adenosine,
we used the A1 receptor antagonist, 1,3-dipropyl-8-cyclopen-
tylxanthine (DPCPX) at a concentration (10 nM) 20 times
higher its anity value for the A1 receptors in the
hippocampus (see Sebastia˜o et al., 1990). At this concentra-
tion, DPCPX increased the slope of the field EPSPs by
21+4.2% (n=20, P50.05), which is consistent with its ability
to prevent the tonic inhibition of synaptic transmission caused
by endogenous adenosine.
When applied to hippocampal slices in the absence of
DPCPX, CGRP in low nanomolar concentrations (1 – 30 nM)
was virtually devoid of eect on the field EPSPs. However, as
illustrated in Figure 1, when CGRP (30 nM) was applied to an
hippocampal slice after a stable response to DPCPX was
recorded, the neuropeptide caused a consistent and reversible
increase (17+1.3%, n=19, P50.05) in the slope of the field
EPSPs. The maximal eect of the neuropeptide was obtained
15 – 20 min after starting CGRP perfusion and was reversed
within 15 – 20 min after stopping CGRP perfusion (Figure 1).
In Figure 2 are compared the concentration-response
curves for the eects of CGRP on the slope of field EPSPs
recorded in the absence and in the presence of DPCPX
(10 nM). In the presence of this A1 receptor antagonist, but
not in its absence, CGRP concentration-dependently
increased the slope of the field EPSPs when tested in
concentrations up to 30 nM. At an higher concentration
(100 nM) CGRP inhibited the slope of the field EPSPs by
15+6.2% (n=3), an action virtually not modified when A1
receptors were blocked by DPCPX (10 nM), the average
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inhibition caused by CGRP under this condition being
13+3.9% (n=3) (Figure 2).
Influence of combined A1 and A2A adenosine receptors
blockade, and of removal of endogenous adenosine, on
the eect of CGRP on synaptic transmission
In a first set of experiments we applied CGRP to
hippocampal slices where A1 and A2A adenosine receptors
have been blocked. To antagonize A2A receptors we used the
selective antagonist, ZM 241385, which has been shown to
prevent adenosine A2A receptor-mediated actions in the
hippocampus (Cunha et al., 1997); CGRP was tested in the
concentration (30 nM) that caused maximal enhancement of
the field EPSPs in the presence of DPCPX (10 nM). As
illustrated in Figure 3A, CGRP (30 nM) was virtually devoid
of eect on the field EPSPs when applied to slices where
both A1 and A2A adenosine receptors have been previously
blocked with DPCPX (10 nM) and ZM 241385 (10 nM). By
itself, ZM (10 nM), applied in the presence of DPCPX
(10 nM), was virtually devoid of eect on the slope of EPSPs
(per cent change of the field EPSP slope: 0.2+2.5%, n=3),
which confirms previous observations (Cunha et al., 1997).
The simultaneous perfusion of ZM 241385 (10 nM) and
DPCPX (10 nM) increased EPSP slope by 25+1.2% (n=3),
an increase that was not significantly dierent (P40.05)
from that obtained (21+4.2%, n=20) with DPCPX (10 nM)
alone.
In another set of experiments we applied the A2A receptor
antagonist only after the full excitatory action of CGRP
(30 nM) in the presence of the DPCPX (10 nM) had been
observed. Under these conditions, CGRP (30 nM) increased
the field EPSP slope by 18+5.4% (n=4, P50.05) and ZM
241385 (10 nM) was unable to reverse this excitatory eect
of the neuropeptide. (Figure 3B).
To further evaluate how A2A receptor activation by
endogenous adenosine was needed for the enhancement of
synaptic transmission caused by CGRP upon A1 receptor
blockade, experiments were designed to test the influence of
adenosine deaminase, an enzyme that inactivates extracel-
lular adenosine into inosine, in that action of CGRP.
Adenosine deaminase (2 U ml71) was applied to hippocam-
pal slices in the presence of DPCPX (10 nM) and, as
expected from the lack of eect of the A2A antagonist on
field EPSPs, the enzyme was also virtually devoid of eect
(per cent change of field EPSP slope: 72.5+2.3%, n=4,
after 20 min application) on field EPSP slope. In these slices,
the subsequent application of CGRP (30 nM) did not
appreciable aect the field EPSPs (per cent change of the
slope: 1.3%+2.4, n=4). As expected, in parallel slices from
Figure 1 Enhancement caused by calcitonin gene-related peptide
(CGRP, 30 nM) on the slope of field excitatory postsynaptic
potentials (fEPSPs) recorded from the CA1 area of an hippocampal
slice in the presence of the A1 adenosine receptor antagonist, 1,3-
dipropyl-8-cyclopentylxanthine (DPCPX, 10 nM). The upper panel
shows the time course of the eect of CGRP. Each point, in the
ordinates, corresponds to the slope of the average of eight
consecutive field EPSPs, and in the abscissae to the start of
averaging. The time of perfusion of CGRP is indicated by the
horizontal bar, and DPCPX (10 nM) was always present. The lower
panel shows recording of field EPSPs (each an average of eight
consecutive responses) obtained (from left to right): before perfusion
of CGRP, at the maximum eect of CGRP (30 nM), and after
washing out CGRP; the field EPSPs are preceded by the synaptic
volley and the stimulus artefact.
Figure 2 Concentration-response curves for the eects of calcitonin
gene-related peptide (CGRP) on the slope of field excitatory
postsynaptic potentials (fEPSPs) recorded from the CA1 area of
the rat hippocampal slices in the absence and in the presence of the
A1 adenosine receptor antagonist, 1,3-dipropyl-8-cyclopentylxanthine
(DPCPX), as indicated by the symbols. Each point represents the
mean+s.e.mean results obtained in n slices, as indicated close to each
symbol. The concentration-response curves were obtained in a non-
cumulative way, and in each slice CGRP was applied only once. The
field EPSP slope before CGRP (0%) was 0.41+0.05 mV ms71
(n=12) in the experiments without DPCPX and 0.48+0.03 mV ms71
(n=30) in the experiments with DPCPX. *P50.05 (Student’s t-test)
as compared with the eect of CGRP in the absence of DPCPX.
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the same hippocampus, GCRP (30 nM) applied in the
presence of DPCPX (10 nM) but in the absence of adenosine
deaminase, increased the slope of the EPSPs by 15+2.3%
(n=4, P50.05)
Influence of A2A receptor activation upon the eect of
CGRP on hippocampal synaptic transmission
The results obtained with the simultaneous blockade of A1 and
A2A receptors suggested that the induction of the excitatory
eect of CGRP in the presence of DPCPX requires tonic
activation of A2A receptors by endogenous adenosine. To
further evaluate how A2A receptor activation interferes with
the action of CGRP on synaptic transmission in the
hippocampus, we tested the action of this neuropeptide in
slices where the A2A adenosine receptors have been activated
by the A2A agonist, CGS 21680. By itself, CGS 21680 (10 nM)
increased the slope of field EPSPs by 8.7+1.7% (P50.05) in
seven out of 12 experiments. In five experiments CGS 21680
was virtually devoid of eect on the field EPSPs. This
variability in the eect of the A2A receptor agonist in the
hippocampus has been previously reported (Sebastia˜o &
Ribeiro, 1992; Li & Henry, 1998).
As illustrated in Figure 4A, CGRP (30 nM) caused a
marked and reversible increase in the slope of the field EPSPs
when applied to hippocampal slices in the presence of the A2A
agonist, CGS 21680 (10 nM). The facilitation of synaptic
transmission caused by CGRP (3 – 30 nM) in the presence of
CGS 21680 (10 nM) was concentration-dependent (Figure 4B),
30 nM CGRP increasing the slope of the field EPSPs by
36+8.2% (n=5, P50.05), an eect which is significantly
larger (P50.05) than that observed in other experiments using
the same concentration of CGRP but in the presence of 10 nM
DPCPX (17+1.3%, n=19). Interestingly, the ability of the
A2A agonist to unmask the facilitatory eect of CGRP on
synaptic transmission does not appear to depend on its ability
to facilitate synaptic transmission, since in the hippocampal
slices where CGS 21680 (10 nM) did not increase the field
EPSP slope, CGRP (3 – 30 nM) applied in the presence of CGS
21680 did facilitate synaptic transmission.
Influence of PK-A blockade or KATP channels blockade
on the eect of CGRP on synaptic transmission
To evaluate the influence of the activity of protein kinase-A
(PK-A) on the eect of CGRP we tested whether HA-1004 or
Figure 3 Influence of the blockade of A2A adenosine receptors with
the selective antagonist, ZM 241385 (10 nM), upon the enhancement
caused by calcitonin gene related peptide (CGRP, 30 nM) on the
slope of field excitatory postsynaptic potentials (fEPSPs) recorded
from the CA1 area of rat hippocampal slices. (A) Represents the
results obtained in the experiments (n=3) in which ZM241385 was
applied before CGRP and (B) represents the results obtained in the
experiments (n=4) in which ZM241385 was applied after the full
eect of CGRP. The presence (+) or absence (7) of each drug is
indicated below each column. In each panel the sequence of drug
application corresponds to the sequence of columns. The field EPSP
slope in the absence of any drugs was 0.45+0.02 mV ms71 in (A)
and 0.48+0.11 mV ms71 in (B). *P50.05 (one-way repeated
measures ANOVA followed by the Newman-Keuls test) as compared
with the field EPSP slope recorded in the same slices before
application of CGRP (first column in each panel). Note that
ZM241385 prevented (A), but did not reverse (B), the excitatory
eect of CGRP.
Figure 4 Enhancement caused by calcitonin gene-related peptide (CGRP) of the slope of field excitatory postsynaptic potentials
(fEPSPs) recorded from the CA1 area of the rat hippocampal slices in the presence of the A2A receptor agonist, CGS 21680 (10 nM).
(A) Shows the time course of the eect of CGRP obtained in one slice. Each point, in the ordinates, corresponds to the slope of the
average of eight consecutive field EPSPs, and in the abscissae to the start of averaging. The time of perfusion of CGRP (30 nM) is
indicated by the horizontal bar and CGS 21680 (10 nM) was always present. (B) Shows the percentage enhancement of the field
EPSP slope caused by dierent concentrations of GCRP. Each point represents the mean+s.e.m. results obtained in three to five
slices obtained from dierent animals. The concentration-response curves were obtained in a non-cumulative way, and in each slice
CGRP was applied only once, and after a stable response to CGS 21680 (10 nM) was obtained. Average field EPSP slope in control
conditions (0%, presence of 10 nM CGS 21680): 0.49+0.04 mV ms71 (n=12). *P50.05 as compared with 0% (Student’s t-test).
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RpcAMPS, two PK-A inhibitors (Hidaka & Kobayashi, 1992;
Rothermel & Parker-Bothelho, 1998), aected the ability of
CGRP to enhance the slope of field EPSPs. When applied to
hippocampal slices in the presence of DPCPX (10 nM), neither
HA-1004 (10 mM) nor RpcAMPS (50 mM) caused appreciable
changes in the slope of the field EPSPs (per cent change:
73.5+3.2%, n=5, for HA-1004 and 72.4+4.7%, n=3, for
RpcAMPS); however, the subsequent application of CGRP
(30 nM) to these slices failed to increase the slope of the field
EPSPs (1.8+1.7%, n=5, in the HA-1004 experiments, and
70.76+3.2%, n=3, in the RpcAMPS experiments). As
illustrated in Figure 5, CGRP (30 nM) increased the slope of
the field EPSPs (16+1.4%, n=6, P50.05) when applied to
parallel slices in the presence of DPCPX (10 nM) but in the
absence of the PK-A inhibitors.
In Figure 5 is also illustrated the ability of the inhibitor of
ATP dependent potassium channels (KATP channels), glib-
enclamide, to prevent the excitatory eect of CGRP on
synaptic transmission. By itself, and when applied to
hippocampal slices in the presence of DPCPX (10 nM),
glibenclamide (30 mM) caused a decrease (15+4.9%, n=7,
P50.05) of the slope of the field EPSPs. In six experiments
using glibenclamide (30 mM) plus DPCPX (10 nM), CGRP
(30 nM) failed to modify the EPSP slope in the presence of
glibenclamide (per cent change: 1.7+0.7%) but increased
EPSP slope (17+5%) in the absence of the KATP channels
inhibitor.
Discussion
To observe an exciatory action of CGRP on synaptic
transmission in the CA1 area of the hippocampus it was
necessary to block A1 adenosine receptors with its selective
antagonist, DPCPX or to activate A2A adenosine receptors
with its selective agonist, CGS 21680. The enhancement of
synaptic transmission caused by CGRP upon blockade of A1
adenosine receptors requires activation of excitatory A2A
adenosine receptors by endogenous adenosine, since the
selective A2A receptor antagonist ZM 241385, or adenosine
deaminase, applied before CGRP, could prevent the facil-
itatory eect of this neuropeptide. Interestingly, when applied
after the full eect of CGRP, ZM 241385 was unable to revert
the excitatory action of the neuropeptide. This precludes the
remote possibility that the A2A agonist was directly interfering
with the CGRP receptors and suggests that tonic activation of
A2A adenosine receptors is required for the induction but not
for the maintenance of the excitatory action of CGRP on
hippocampal synaptic transmission.
The ability of DPCPX and of CGS 21680 to trigger an
excitatory action of CGRP on synaptic transmission in the
hippocampus does probably not result solely from their
facilitatory action on synaptic transmission, since (1) the
simultaneous perfusion of DPCPX and ZM 241385 also
caused an increase in the field EPSP slope but, under these
conditions, CGRP was unable to facilitate synaptic transmis-
sion and (2) CGS 21680 was able to trigger an excitatory action
of CGRP even in the experiments where the A2A agonist was
unable to facilitate synaptic transmission.
A schematic diagram of the probable interplay between
CGRP and A1 or A2A receptors is represented in Figure 6. It is
known that the main tonus of endogenous adenosine in the
hippocampus, at least in the experimental conditions used, is
inhibitory (e.g. Dunwiddie & Diao, 1994; Cunha et al., 1996).
Thus, the absence of eect of CGRP alone and its eect in the
presence of DPCPX are highly suggestive that endogenous
adenosine, by activating A1 receptors, is tonically restraining
the action of CGRP. Relieve of this inhibition by DPCPX
allows the initiation of the action of CGRP providing that the
A2A receptors are operative to be activated by endogenous
adenosine. Instead of blockade of A1 receptors, activation of
Figure 5 Blockade by the protein kinase A inhibitor, HA-1004
(10 mM), and by the inhibitor of KATP channels, glibenclamide
(30 mM), of the facilitatory action of calcitonin gene related peptide
(CGRP, 30 nM) on field excitatory postsynaptic potentials (EPSPs)
recorded from the CA1 area of rat hippocampal slices. The
recordings were obtained in the same experiment, using three
hippocampal slices from the same hippocampus. Each panel shows
two superimposed field EPSPs (each an average of eight consecutive
responses) from the same slice obtained immediately before (control,
C) and 20 min after CGRP perfusion, as indicated by the arrows.
The eect of CGRP was tested first in the absence (upper panel),
than in the presence of HA-1004 (middle panel) or glibenclamide
(lower panel). The adenosine A1 receptor antagonist, DPCPX
(10 nM) was present throughout the experiment. In this experiment,
the per cent modification of the field EPSP slope caused by HA-1004
(10 mM) and glibenclamide (30 mM) was 70.5% and 76%,
respectively.
Figure 6 Schematic diagram of the model proposed for the
interactions between adenosine (ADO) and CGRP in the hippocam-
pus. Tonic activation of A1 adenosine receptors by endogenous
adenosine is indicated by the double arrow. An inhibitory interaction
is indicated by (7) and a facilitatory interaction is indicated by (+).
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A2A receptors with its agonist, CGS 21680, was also able to
trigger an excitatory action of CGRP on synaptic transmis-
sion. It is known that A2A adenosine receptor activation by
CGS 21680 inhibits A1 receptor functioning in the hippocam-
pus (Cunha et al., 1994). Thus, the A1 adenosine receptors are
less operative in the presence of CGS 21680 and this may
contribute to the ability of the A2A agonist to trigger the
facilitatory action of CGRP on synaptic transmission.
However, this A2A/A1 adenosine receptor interaction is
probably not the only mechanism by which A2A receptor
activation induces the ability of CGRP to enhance synaptic
transmission, since the eect of this neuropeptide was greater
in the presence of the A2A agonist, CGS 21680, than in the
presence of the A1 antagonist, DPCPX.
CGRP receptors are positively coupled to adenylate cyclase
in a variety of tissues (for a review see Wimalawansa, 1996),
and evidence has been provided that stimulation of adenylate
cyclase, increased production and accumulation of cyclic
AMP, and activation of PK-A, mediates activation of KATP
channels by GCRP (Wellman et al., 1998). The present
observations that the excitatory action of CGRP on synaptic
transmission is prevented by inhibitiors of PK-A, as well as by
a KATP channel blocker, is also consistent with an involvement
of PK-A and KATP channels in the action of CGRP in the
hippocampus. A2A adenosine receptors are in most cases
positively coupled to adenylate cyclase (see Sebastia˜o &
Ribeiro, 1996). It is conceivable that A2A receptor activation,
by causing local enhancement of cyclic AMP levels, acts as a
primer of the transducing system operated by CGRP in the
hippocampus, which might explain the presently observed
positive interaction between A2A receptors activation and the
action of CGRP on synaptic transmission.
The predominant inhibitory tonus by endogenous adeno-
sine in the hippocampus (Dunwiddie & Diao, 1994), might
explain why CGRP by itself is unable to aect synaptic
transmission. This contrasts with what occurs at motor nerve
terminals, where endogenous adenosine tonically activates A2A
receptors (Correia-de-Sa´ et al., 1996), and CGRP by itself
facilitates neurotransmitter release (Correia-de-Sa´ & Ribeiro,
1994). Interestingly, as it occurs in the hippocampus (present
results), blockade of A2A receptors prevents the facilitatory
action of CGRP at motor nerve terminals (Correia-de-Sa´ &
Ribeiro, 1994).
In conclusion, the results presented in this paper show that
the ability of CGRP to facilitate synaptic transmission in the
CA1 area of the hippocampus is under tight control by
adenosine, with the A1 receptors ‘braking’ the action of CGRP
and the A2A receptors ‘triggering’ this action. The need of A2A
receptor activation by endogenous adenosine to reveal the
excitatory action of CGRP on synaptic transmission in the
hippocampus, taken together with the observation that the
induction of the excitatory action of CGRP on synaptic
transmission caused by CGS 21680 was more evident and
consistent than the enhancement of synaptic transmission
caused by the A2A receptor agonist itself, suggests that a main
role A2A adenosine receptors in the hippocampus is to
modulate the action of other neuromodulators and, by this
process, to contribute for a sophisticated ‘fine tune’ of
hippocampal functioning.
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